08.04.26 -- The Great CDMO Reset: How Sponsor Expectations Are Driving Change

Switching from bacterial plasmids to cell-free circular ssDNA boosts gene-editing safety and precision, reduces toxicity, enables up to 75% knock-in efficiency, and improves primary cell viability.

NGS transcriptome methods offer a sensitive, animal-free alternative for detecting viruses in cell banks. Analyzing total mRNA transcripts enables precise identification and regulatory compliance.

Learn why it's important to stay aligned with evolving Annex 1 expectations to support sterility assurance, regulatory compliance, and patient safety across sterile drug manufacturing operations.

Bridging the gap between early cell therapy development and clinical manufacturing requires operational continuity. Standardizing automated equipment eliminates technology transfer friction.

Early CMC and expression system decisions in recombinant protein development shape quality, cost, and manufacturability, while cross-functional collaboration helps avoid bottlenecks.

Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.

See the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.

Automated at‑line immunophenotyping QC streamlines cell therapy manufacturing, cutting turnaround time and cost while aligning with conventional methods and enabling scalable, reliable workflows.

Assimilate how streamlined vector backbones can improve efficiency, consistency, and expression durability when reliability matters most.

Expedited cell therapy pathways demand early, reliable analytical development to ensure data, regulatory confidence, and smooth transitions from discovery through clinical stages without delays.

Poly(A) tail integrity is critical for mRNA stability and translation. Advanced strategies optimize plasmid design, transcription, and purification to ensure consistent poly(A) control for therapeutic success.

The streamlined AAV transient transfection platform de-risks your path to IND and reduces complexity and timeline for lengthy process and analytical development.

Transitioning to distributed manufacturing can reduce costs, overcome infrastructure barriers, and expand access to advanced cell therapies for oncology patients worldwide.